



Frequency of selected genetic polymorphisms of cytochrome P450 in the Czech 
population and the influence of CYP2C9 genotype on the hypolipidemic effect of 
fluvastatin 
 
Introduction: One of the main factors of genetically determined variability in response of 
humans to administered drugs are differences in catalytic activity of metabolizing enzymes, 
which are caused mainly by genetic polymorphisms in cytochrom P450 family enzymes. This 
thesis consists of two parts and it is presented as a commentary to the original papers. The 
first aim was to investigate the frequency of functionally important variant alleles of three 
main isoenzymes of cytochrome P450 gene: CYP2D6, CYP2C9, CYP2C19, throughout the 
Czech population, predict the prevalence of poor metabolizer phenotypes, and then to 
compare the results to the data from other populations. Secondly, we analysed the correlation 
between the CYP2C9 genotype and cholesterol-lowering effect of fluvastatin in human 
hypercholesterolemic patients. 
Methods: Genotypes were determined by PCR–RFLP. The presence of alleles CYP2D6*1, 
*6, *5, *4, *3, and gene duplication was analysed in 233 healthy volunteers,  CYP2C9*1, *2 
and*3 in 254 subjects and CYP2C19*1, *2 and *2 in 218 subjects. Eighty seven patients on 
fluvastatin therapy, and 48 patients on monotherapy were enrolled in the prospective 
fluvastatin study without any interventions to standard procedures of hypolipidemic treatment. 
Biochemical and clinical data were collected before the initiation of fluvastatin treatment (80 
mg/day) and 12 weeks later. 
Results and conclusions: There are 6.7%  of CYP2D6 poor metabolizers and about 2% of 
CYP2C19 and CYP2C9 poor metabolizers in the Czech population. The frequencies of the 
most important functional variant alleles of CYP2D6, CYP2C9 and CYP2C19 and their 
predicted phenotypes in the Czech population are in concordance with other Caucasian 
populations. The hypolipidemic effect of fluvastatin was found to be partly influenced by 
CYP2C9 genotype. Subjects with the CYP2C9*1/*3 genotype achieved a greater reduction in 
plasma levels of LDL-cholesterol than subjects with CYP2C9*1/*1 or *1/*2 genotypes 
(39.95% vs. 22.35% or 29.92% respectively), and similar trend was observed in reduction of 
total cholesterol levels. However, due to rare occurrence of the *3/*3 genotype it was 
impossible to report a definitive genotype-effect association. 
 
In conclusion, by implementing the genotyping methods and by detemining the 
frequency of occurence of the main genetic polymorphisms in CYP isoenzymes, which were 
reported to account for the metabolism of 40% of administered drugs, we have laid basis for 
future research into the clinical applications and the development of individualized 
pharmacotherapy. 
 
Keywords: cytochrome P450, CYP2D6, CYP2C9, CYP2C19, single nucleotide 
polymorphism, pharmacogenetics, Czech population, individualized pharmacotherapy, 
fluvastatin, hypercholesterolemia 
 
